- Home
- GLMD vs XRTX Comparison
GLMD vs XRTX Comparison
Compare GLMD & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLMD | XRTX |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 4.3M |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GLMD | XRTX |
|---|---|---|
| Price | $0.60 | $2.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 80.4K | 61.3K |
| Earning Date | 05-21-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.35 |
| 52 Week High | $2.34 | $3.60 |
Technical Indicators
Market Signals| Indicator | GLMD | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.01 | 46.82 |
| Support Level | $0.53 | $1.98 |
| Resistance Level | $0.69 | $3.03 |
| Average True Range (ATR) | 0.05 | 0.28 |
| MACD | -0.00 | -0.10 |
| Stochastic Oscillator | 14.51 | 23.42 |
Price Performance
Historical ComparisonAbout GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.